B-cell Non Hodgkin Lymphoma Clinical Trials

103 clinical trials for B-cell Non Hodgkin Lymphoma across international registries, including 33 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL — RECRUITING · PHASE2
• A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies — RECRUITING · PHASE1
• CD45BE-HSPC + CART-45 Cells — RECRUITING · PHASE1
• A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas — RECRUITING · PHASE1
• A Study of ARC-02 in B-cell NHL — RECRUITING · PHASE1
• Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients — RECRUITING · PHASE1
• A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies — RECRUITING · PHASE1
• A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma — RECRUITING · PHASE1
• Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies — RECRUITING · PHASE1
• Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE2
• A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma — RECRUITING · PHASE1
• UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL — RECRUITING · PHASE1
• Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL — RECRUITING · PHASE1
• Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE2
• B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies — RECRUITING · PHASE1
• CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors — RECRUITING · PHASE2
• A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies — RECRUITING · NA
• Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL — RECRUITING · PHASE1
• A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 ) — RECRUITING · PHASE1
• Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study — RECRUITING · PHASE2
• Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) — RECRUITING · PHASE1
• Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL — RECRUITING · PHASE1
• A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma — RECRUITING · PHASE1
• Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma — RECRUITING · PHASE1
• Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment — ACTIVE_NOT_RECRUITING · PHASE2
• AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA — TERMINATED · PHASE2
• A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies — ACTIVE_NOT_RECRUITING · PHASE2
• Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study — COMPLETED
• Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• INfections in Patients Treated With CAR-T — NOT_YET_RECRUITING
• A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) — NOT_YET_RECRUITING · PHASE1
• A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance — ACTIVE_NOT_RECRUITING · PHASE1
• A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma — NOT_YET_RECRUITING · PHASE1
• A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies — NOT_YET_RECRUITING · PHASE1
• Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — NOT_YET_RECRUITING · PHASE1
• A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE3

Refine this search